Hey volume picked up on the mighty WallBox yesterday and it jumped 5% almost. I still maintain the company is overpriced, but it might be starting a move north on a short squeeze.
GBA Presents: THE BARE ESSENTIALS
- Thread starter stonedinvestor
- Start date
Hey volume picked up on the mighty WallBox yesterday and it jumped 5% almost. I still maintain the company is overpriced, but it might be starting a move north on a short squeeze.
I know I immediately thought of Captain Ron
Travelzoo reports Q1 cont ops EPS 19c, consensus 6c 07:31 TZOO Reports Q1 revenue $18.5M, consensus $16.67M.
Travelzoo sees 'higher revenue and profitability in Q2' 07:32 TZOO The company said,…
Here is a name I feel we had the correct concept but the investment never worked out---
Clear Secure launches expedited lanes at San Diego International Airport 08:05 YOU As airports across the…
I gave this next idea out ages ago I was forced out-
Gamida Cell presents updated Omidubicel data 20:20 GMDA Gamida Cell "announced that updated infection data on omidubicel in comparison to umbilical cord blood transplantation, was shared in an oral presentation at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings, being held in Salt Lake City, UT, April 23-26, 2022."
Gamida Cell receives FDA clearance for GDA-201 IND, clinical hold removed 07:20 GMDA Gamida Cell announced that the FDA cleared its investigational new drug, or IND, application and removed the clinical hold for a cryopreserved formulation of GDA-201. GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas. Gamida Cell expects to initiate a company-sponsored Phase 1/2 clinical study in patients with follicular and diffuse large B-cell lymphomas in 2022.
Staar Surgical price target raised to $89 from $81 at Canaccord 07:26 STAA Canaccord analyst William Plovanic raised the firm's price target on Staar Surgical to $89 from $81 and keeps a Buy rating on the shares. The analyst noted they received US FDA approval for EVO in late March 2022 and immediately began US commercialization, with first US implants performed on March 28. His target increase reflects the increase in the comp group multiple.
This Co is very hard to figure out- sort of a baby 3M they have their hands in a lot of jars and lots of innovation-
Entegris reports Q1 non-GAAP EPS $1.06, consensus 99c 06:05 ENTG Reports Q1 revenue $650M, consensus $640.85M. Bertrand Loy, Entegris' president and CEO, said: "We delivered a record performance in the Q1. These results were driven in large part by our team's great execution, in what remains a dynamic operating environment. Growth was significant across all three divisions, driven by robust industry conditions and more wafers produced at the leading edge, which continues to translate into strong demand for our solutions."
https://www.youtube.com/watch?v=KzGc9X7MDl0
New Fortress Energy application for LNG solution in U.S. GOM advances 06:11 NFE New Fortress Energy…
https://www.youtube.com/watch?v=OoXUgEb6Zuo
Northern Oil and Gas price target raised to $36 from $31 at Citi 06:16 NOG Citi analyst Scott Gruber…
DIVERSITY CHECK-
https://www.youtube.com/watch?v=C-qWlVV3Hqo
Travelzoo reports Q1 cont ops EPS 19c, consensus 6c 07:31 TZOO Reports Q1 revenue $18.5M, consensus $16.67M.
Travelzoo sees 'higher revenue and profitability in Q2' 07:32 TZOO The company said,…
Here is a name I feel we had the correct concept but the investment never worked out---
Clear Secure launches expedited lanes at San Diego International Airport 08:05 YOU As airports across the…
I gave this next idea out ages ago I was forced out-
Gamida Cell presents updated Omidubicel data 20:20 GMDA Gamida Cell "announced that updated infection data on omidubicel in comparison to umbilical cord blood transplantation, was shared in an oral presentation at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings, being held in Salt Lake City, UT, April 23-26, 2022."
Gamida Cell receives FDA clearance for GDA-201 IND, clinical hold removed 07:20 GMDA Gamida Cell announced that the FDA cleared its investigational new drug, or IND, application and removed the clinical hold for a cryopreserved formulation of GDA-201. GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas. Gamida Cell expects to initiate a company-sponsored Phase 1/2 clinical study in patients with follicular and diffuse large B-cell lymphomas in 2022.
Staar Surgical price target raised to $89 from $81 at Canaccord 07:26 STAA Canaccord analyst William Plovanic raised the firm's price target on Staar Surgical to $89 from $81 and keeps a Buy rating on the shares. The analyst noted they received US FDA approval for EVO in late March 2022 and immediately began US commercialization, with first US implants performed on March 28. His target increase reflects the increase in the comp group multiple.
This Co is very hard to figure out- sort of a baby 3M they have their hands in a lot of jars and lots of innovation-
Entegris reports Q1 non-GAAP EPS $1.06, consensus 99c 06:05 ENTG Reports Q1 revenue $650M, consensus $640.85M. Bertrand Loy, Entegris' president and CEO, said: "We delivered a record performance in the Q1. These results were driven in large part by our team's great execution, in what remains a dynamic operating environment. Growth was significant across all three divisions, driven by robust industry conditions and more wafers produced at the leading edge, which continues to translate into strong demand for our solutions."
https://www.youtube.com/watch?v=KzGc9X7MDl0
New Fortress Energy application for LNG solution in U.S. GOM advances 06:11 NFE New Fortress Energy…
https://www.youtube.com/watch?v=OoXUgEb6Zuo
Northern Oil and Gas price target raised to $36 from $31 at Citi 06:16 NOG Citi analyst Scott Gruber…
DIVERSITY CHECK-
https://www.youtube.com/watch?v=C-qWlVV3Hqo
- Blink Charging (NASDAQ:BLNK) has acquiredUK-based EV infrastructure provider, Electric Blue (EB Charging), in a ~$23.4M cash, stock and earn out transaction.
- The acquisition was made through Blink's wholly-owned European subsidiary, Blink Holdings.
- EB Charging specializes in integrated EV charging and sustainable energy solutions. The acquisition marks Blink's first foray into the UK, adding over more than 1,150 EV chargers to its global footprint.
- Michael Farkas, Founder and CEO of Blink Charging stated, "Blink will be working with EB Charging to establish a Blink presence in the UK, allowing us to bring a unified global experience. Blink will expand EB Charging’s product offerings to include new commercial and home chargers, new global network services and apps, and new EV fleet management tools.
Gamida stock soars 32% as FDA lifts hold on GDA-201, to start trial for treating blood cancer///
- International Game Technology PLC (NYSE:IGT)announcedthat it has become the first U.S. supplier in the gaming industry to receive Global Gambling Guidance Group responsible gaming accreditation for its sports betting operations.
- G4 aims tominimize the impact of problem gaming by promoting a worldwide accreditation program for the remote and e-gambling industry and operators.
- IGT is now G4 certified in responsible gaming across its four product segments encompassing lottery, gaming, digital and betting.
- "IGT's proactive approach to responsible gaming and achieving prestigious G4 certifications sets the pace for the entire industry to go above and beyond what state regulation mandates when it comes to player protection," said Joe Asher, IGT President of Sports Betting. "
- IGT received G4 responsible gaming certification for its gaming operations in 2017 and its digital solutions in 2019. Additionally, IGT's lottery and iLottery businesses are certified by the World Lottery Association for WLA's Corporate Social Responsibility Standards and Responsible Gaming Framework for Suppliers.
PFIZER Remains In The Bare Essential portfolio...!!! But it still won't move!
US aims to boost use of Pfizer COVID drug Paxlovid with greenlight to pharmacies - Bloomberg
US aims to boost use of Pfizer COVID drug Paxlovid with greenlight to pharmacies - Bloomberg
Pfizer (NYSE:PFE) Valneva (NASDAQ:VALN) said they plan to include children above 5 years of age in a planned phase 3 trial of their Lyme disease vaccine VLA15 after positive pediatric data was reportedfrom a phase 2 trial, which included children aged 5 years to 17 years, among others.
The study compared the immunogenicity and safety of VLA15 after administration of two (at months 0 and 6) or three (at months 0, 2 and 6) primary series doses in groups aged 5-11 years, 12-17 years and 18-65 years.
The companies said that in children 5 years to 17 years who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested.
The companies hadreporteddata for people 18 years to 65 years old in February.
The companies added that like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in children in the phase 3 study.
The safety and tolerability profile seen in the 5- to 17-year age group was similar to the previously reported profile in adults.
No vaccine-related serious adverse events (SAEs) were seen, the companies noted.
Based on these new results, Valneva (VALN) and Pfizer (PFE) plan to proceed with inclusion of children in their planned Phase 3 study.
The trial will evaluate VLA15 in adults and children 5 years of age and above and is expected to be started in Q3 2022, subject to regulatory approval.
VALN+1.97%to $28.96 premarket April 26<------
Might be worth keeping track of VALN.
Lyme is a huge problem & growing although 3 shots is a bit much.
The study compared the immunogenicity and safety of VLA15 after administration of two (at months 0 and 6) or three (at months 0, 2 and 6) primary series doses in groups aged 5-11 years, 12-17 years and 18-65 years.
The companies said that in children 5 years to 17 years who received VLA15 in either the two-dose schedule (N=93) or three-dose schedule (N=97), VLA15 was found to be more immunogenic than in adults with both vaccination schedules tested.
The companies hadreporteddata for people 18 years to 65 years old in February.
The companies added that like in adults, the immunogenicity and safety data support a three-dose primary vaccination schedule in children in the phase 3 study.
The safety and tolerability profile seen in the 5- to 17-year age group was similar to the previously reported profile in adults.
No vaccine-related serious adverse events (SAEs) were seen, the companies noted.
Based on these new results, Valneva (VALN) and Pfizer (PFE) plan to proceed with inclusion of children in their planned Phase 3 study.
The trial will evaluate VLA15 in adults and children 5 years of age and above and is expected to be started in Q3 2022, subject to regulatory approval.
VALN+1.97%to $28.96 premarket April 26<------
Might be worth keeping track of VALN.
Lyme is a huge problem & growing although 3 shots is a bit much.
Graphic Packaging Holding Non-GAAP EPS of $0.48 beats by $0.10, revenue of $2.24B beats by $50M- watch for gummy!
No reaction to a $50 mln beat!
GPK Pre
21.08
21.08
-2.04%
0.00%
Apr. 26, 2022 6:35 AM ETGraphic Packaging Holding Company (GPK)
No reaction to a $50 mln beat!
GPK Pre
21.08
21.08
-2.04%
0.00%
Apr. 26, 2022 6:35 AM ETGraphic Packaging Holding Company (GPK)
- Graphic Packaging Holdingpress release(NYSE:GPK): Q1 Non-GAAP EPS of $0.48beats by $0.10.
- Revenue of $2.24B (+35.8% Y/Y)beats by $50M.
Energy regains some ground Monday as natural gas squeezes 6% into the close
i'd like to get out from under both of these... the penny stocks i've been playing have been oddly a lot more reliable then messing around with speculative stuff on the big boards.